COGT Insider Trading Activity and SEC Form 4 Filings
COGT insider trading summary
Over the past 12 months, insiders at Cogent Biosciences, Inc. (COGT) reported 4 sales worth $371.7M by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $371.7M.
Latest COGT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morris | Insider | Sell | $119K (3,161 @ $37.54) |
| Aug 27, 2026 | Arlene Morris | Insider | Sell | $1.6M (42,349 @ $37.09) |
| Mar 31, 2026 | Fairmount Funds Management LLC | Director | Sell | $242.6M (7,000,000 @ $34.66) |
| Jan 22, 2026 | Fairmount Funds Management LLC | Director | Sell | $127.4M (3,500,000 @ $36.40) |
| Jul 10, 2025 | Fairmount Funds Management LLC | Director | Buy | $25.0M (2,777,777 @ $9.00) |
| Jan 14, 2025 | Cole Pinnow | Chief Commercial Officer | Buy | $332K (43,750 @ $7.60) |
| Jun 9, 2023 | Fairmount Funds Management LLC | 10% Owner | Buy | $9.6M (800,000 @ $12.00) |
| Jun 16, 2022 | Fairmount Funds Management LLC | 10% Owner | Buy | $9.9M (1,200,000 @ $8.25) |
| Apr 26, 2021 | John L. Green | Chief Financial Officer | Sell | $158K (17,813 @ $8.86) |
| May 12, 2020 | Dario Campana | 10% Owner | Sell | $46K (98,200 @ $0.46) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.